Our data show that combining ephrin-B2-EphB4 inhibitor with RT significantly reduces regulatory T-cell and neutrophil infiltration, TGFβ1 secretion, and stromal fibrosis, enhancing effector T-cell activation and decreasing tumor growth. The gene discussed is TGFB1; the disease is neoplasm.